1 / 6

Chair: Dr. Vivien Bramwell

NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP. Chair: Dr. Vivien Bramwell. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP. Objectives - short-term.

orpah
Download Presentation

Chair: Dr. Vivien Bramwell

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP Chair: Dr. Vivien Bramwell

  2. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - short-term • To undertake adjuvant studies to reduce recurrence and mortality due to metastases in early ASTS (Intergroup) • GISTACOSOG Z9001 • - will complete accrual in 6 - 12 months • - Canadian accrual approx. 10% • STSINTERGROUP • - Canadian participation in EORTC 62931 (closed • December 2003) • - several Intergroup proposals for RCT have failed, • no agreement on appropriate control arm, • limited efficacy current regimens in advanced STS

  3. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - short-term • To perform empirical screening and/or rationally targeted studies of IND in chemotherapy-naïve patients across spectrum ASTS • four phase II studies completed, published in last 10 yrs • chemo-naïve patients, Intergroup collaboration in EORTC 62012 • – phase III trial of single agent DOX vs dose intense DOX/IFOS • – start Fall 2006

  4. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - short-term • To assess molecularly targeted therapies in histology- specific trials in patients who have failed conventional chemotherapy (Intergroup) • ICAS Intergroup Coalition Against Sarcomas • funded through SWOG operating grant • involves NCIC-CTG, ECOG, CALGB • shared studies with RTOG, ACOSOG, COG • S0033 imatinib in GIST (closed September 2001) • – accrued 746 pts in 9 mos (Canadian 7%) • 4 IND studies open – accruing through SWOG • 3 on CTSU (1 awaiting Canadian activation, 2 declined) • 3 future ICAS CTSU studies – Canadian interest • 1 protocol, Canadian PI (Q. Chu) in development

  5. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - medium-term • To use research findings generated through the CSG TB/DB and/or IHRT program to plan future correlative science projects/clinical trials • CSG TB/DB (approximately 900 frozen/fixed tumors and data) currently funded and maintained as part of larger TB/DB through IHRT program Mt. Sinai, Toronto • IHRT program may morph into CanSarc (pending funding CIHR) • IHRT/CanSarc projects, in future, may need national clinical trials involvement

  6. SARCOMA COMMITTEE/CANADIAN SARCOMA GROUP Objectives - medium-term • To build on local control, survival and functional outcome data from SR2 study, to plan future studies that will optimize local control and reduce morbidity in locoregional ASTS • translational, pilot studies ongoing through IHRT/CanSarc • also may lead to future proposals for multicentre trials

More Related